• Monday, July 30, 2018 @ 12:00 pm

Cassiopea delivered on its “Super Q2” reporting positive clinical trial results for three pipeline projects including: 1) phase III top line results of Winlevi in acne; 2) phase IIb dose ranging interim results of Breezula in alopecia (hair loss); and 3) POC results of CB-06-02 in genital warts. To maximize the long-term value of Winlevi and its other dermatology drugs, Cassiopea plans to commercialize its drugs through an own specialist dermatology field force in the US, and seek commercialization partners outside the US. In H2 2018 a follow-on raise is planned to finance the buildup of the US sales infrastructure.

Key catalysts include:

  •     Start POC trial of Breezula (alopecia) in women (H2 2018)
  •     US NDA filing Winlevi in acne (Q1 2019)
  •     Start phase III trials of Breezula in alopecia (H1 2019)

Finde the full valuation report for download below.

You may also be interested in